Cases & Deals

Torii Pharmaceutical acquires exclusive marketing and licensing rights from BioCryst for BCX7353 in Japan

Clients Torii Pharmaceutical Co., Ltd

Jones Day represented Torii Pharmaceutical Co., Ltd. in drafting, reviewing, and negotiating its commercialization and license agreement with BioCryst Pharmaceuticals, Inc. Torii has acquired exclusive licensing and marketing rights in Japan to market products containing the plasma kallikrein inhibitor BCX7353. The compound is a new oral agent that is expected to prevent hereditary angioedema ("HAE") attacks.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.